Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Mirimus and Biogen, AavantiBio and Aldevron, Exscientia and GT Apeiron Therapeutics announced strategic partnerships this morning.
It will immediately begin to sell Bylvay to treat patients impacted by PFIC, a rare cholestatic liver disease that often leads to cirrhosis and liver failure within the first ten years of life.
As Johnson & Johnson touted $23.3 billion sales on its Q2 earnings call this morning, other news in the media hasn’t been as kind to the massive, global conglomerate.
The company also reported on its COVID-19 vaccine production with CureVac, a drug it is abandoning, and a few specific drug updates.
Notably, Koselugo was studied in pediatric populations first, a reversal of the typical development path taken by the majority of drugs.
More money means more progress for potentially life-saving therapies. Here’s a peek at some biopharma companies adding to their books this week.
The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.
Shares of Arcus Biosciences dipped sharply in post-market trading Monday after it was learned that the company’s chief medical officer was departing for a role at Gilead Sciences.
A new study has found that statins, a popular class of cholesterol-lowering drugs, may decrease the odds of dying from coronavirus disease 2019 (COVID-19) by 41% and reduce the risk of severe disease.
The Boston-based company merged with Capstar Special Purpose Acquisition Corp. and will begin trading on the New York Stock Exchange under the ticker symbol “GLS.”
The salary expectation question is one of the most difficult questions asked during a job interview. Here’s how you can answer the question perfectly.
The Boston-based company announced an infusion of $135 million in Series C funds to support the late-stage development of its lead candidate, AMX0035, for amyotrophic lateral sclerosis.
PRESS RELEASES
· Supporting the development of its proprietary MIC-Lx Modified Immune Cells technology as a novel approach to reduce lifelong systemic immunosuppression and improve long-term outcomes for transplant recipients · Strengthening MIC-Lx’s regulatory and commercial positioning in Europe
- EUR ~8M grant supports the late-stage clinical development of Omnix’s antimicrobial OMN6 - Leading European partners join forces to advance OMN6 for the treatment of life-threatening hospital-acquired infections